Eye disease breakthrough

17th January 2014

The first clinical trial of a gene therapy for an inherited cause of progressive blindness called choroideremia has shown very promising initial results which have surpassed the expectations of the Oxford University researchers leading the study.

The technology is covered by a patent application owned by Oxford University Innovation.

Work is in progress to develop the gene therapy into an approved clinical product through further clinical trials.

Further information is available here.

Press release sign up